Tech giant Samsung Electronics said on Monday it will create a $85.8 million fund to compensate its cancer-stricken workers.» Read More
I don't want to get anyone in trouble, so I won't name the company, the drug or even what it's for. (Note to corporate PR folks reading this: Don't even try to pry it out of me. My lips are sealed.) All I'll say is that it's one of the biggies.
I'm not really enjoying my "day off" so far here in rather gloomy, cool L.A. as I've been kept pretty busy trying to chase down the Dendreon story.
An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.
A prestigious peer-reviewed journal is proposing taking a hardline stance on what it calls the "pervasive" funding relationship between drug and medical device companies and professional medical associations.
Shares of Amylin Pharmaceuticals are rallying on a press release from AMLN and its partners Eli Lilly and Alkermes that their once-a-week version of the injectable diabetes drug Byetta (buy-ate-uh) lowered blood sugar levels more than the pills Januvia from Merck and Actos from Takeda.
A drug from Novartis has won U.S. approval as a treatment for patients with kidney cancer that has returned after treatment with older drugs.
There is no quid pro quo in my line of work. At least there shouldn't be. But when you do two stories on CNBC and another one on "TODAY" that mentions a company's drug and profiles a patient who appears to have been a "responder" in one of its clinical trials you expect a certain basic professional level of cooperation and assistance.
I'm on the road on assignment, but used a little downtime to go through the "Pharma's Market" mailbox. Regarding my farewell to Genentech post yesterday a couple of folks emailed to point out that GENE was Genentech's ticker symbol when it was traded on the Nasdaq back in the day. Then it was GNE on the NYSE before going to the much better DNA.
DNA has always been one of my favorite clever ticker symbols on the biopharma beat. Sure, GENE might've made sense for Genentech if it had been listed on the Nasdaq, but DNA was pretty good. But after today DNA is no more.
Oh, the Dendreon investor message boards are on fire! And my inbox has a few sparks. Matthew Herper at Forbes wrote a piece today daring to question the integrity of the all-important data due out sometime next month on DNDN's prostate cancer treatment Provenge.
All of my, ahem, complaining and whining, to put it politely, about the American Society of Clinical Oncology may not have fallen on deaf ears after all.
Art Levinson and Miles White are "Kings of the Jungle." At least Barron's thinks they are. The weekly investment periodical picked the pair as the only two from biopharma to make its annual list of the "30 Most Respected CEOs."
My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.
Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.
Pfizer announced this morning that it's raising the income levels for uninsured people to qualify for cheaper or free drugs because of the bad economy.
Scientific and medical journals like to keep their distance from the business side of things. That's why I think it's worth noting that a "Perspective" piece--think of it as kind of a newspaper Op-Ed--in "The New England Journal of Medicine" starts by mentioning Pfizer's stock price and its recent proposed acquisition of Wyeth.
Despite my repeated invitations for his first post-jailhouse interview on this blog and through one of his contacts, Sam Waksal didn't respond. Given his Manhattan social scene background it should not, perhaps, come as a surprise that the founder of ImClone Systems decided to have his coming-out party in "New York" magazine.
The overwhelming majority of people who have voted in the “Pharma’s Market” poll about the future of Genentech’s execs and top scientists thinks most of them will eventually bolt.
Last week was a busy week, to say the least, on the Pharma beat - So I was looking forward to the weekend and escaping all things drug-related. But as fate would have it, it ended up being bookended by references to pharma in a couple of surprising venues.
All of a sudden yesterday and today shares of Dendreon —my favorite biotech story—shot up on heavy volume.